Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 2/3/2026

Esmolol Use in Thyroid Storm – Evidence‑Based Recommendations

Epidemiology & Rationale

  • Thyroid storm carries a mortality of 5–25 % and beta‑adrenergic blockade is a cornerstone of its multimodal treatment, as recommended by the American College of Endocrinology and the American Association of Clinical Endocrinologists. 1

Dosing & Administration

  • A regimen of repeated 5 mg IV boluses every 5 minutes (maximum 15 mg total) may be employed for severe refractory tachycardia, followed by a continuous infusion started 15 minutes after the final bolus. (Praxis Medical Insights, 2026) – expert consensus. 2
  • The target heart rate in thyroid storm is 80–100 bpm (more permissive than the 50–60 bpm goal for routine thyrotoxicosis). (Praxis Medical Insights, 2026) – expert consensus. 2

Monitoring Requirements

  • Continuous ECG monitoring is mandatory throughout esmolol infusion to promptly detect bradycardia, heart block, or arrhythmias. (Praxis Medical Insights, 2026) – expert consensus. 2
  • Regular auscultation of the lung fields is required to identify bronchospasm, especially at higher infusion rates where β1‑selectivity may wane. (Praxis Medical Insights, 2026) – expert consensus. 3

Integration with Multimodal Thyroid Storm Therapy

  • Beta‑blockade must be combined with antithyroid drugs (propylthiouracil or methimazole), inorganic iodide (administered ≥1 hour after the antithyroid agent), and corticosteroids, as stipulated by the American College of Endocrinology and the American Association of Clinical Endocrinologists. 1
  • Esmolol provides rapid symptomatic control of adrenergic hyperactivity but does not treat the underlying excess thyroid hormone; definitive hyperthyroidism therapy must proceed concurrently. (Praxis Medical Insights, 2026) – expert consensus. 3
  • Aggressive supportive measures—including antipyretics, external cooling, volume resuscitation, and ICU‑level monitoring—are essential components of guideline‑based care. (American College of Endocrinology & AACE) 1

Transition to Oral Beta‑Blockers

  • After hemodynamic stability and oral tolerance are achieved, patients should be switched to oral propranolol (40–80 mg every 6–8 hours) or metoprolol (25–50 mg every 6 hours). (Praxis Medical Insights, 2026) – expert consensus. 3
  • Oral beta‑blocker therapy should be continued until definitive treatment of hyperthyroidism (radioactive iodine or thyroidectomy) results in euthyroidism. (American College of Endocrinology & AACE) 1

Safety Considerations & Special Populations

  • Prior to and during esmolol infusion, ensure adequate volume resuscitation because thyroid‑storm patients are often volume‑depleted from fever, diaphoresis, and gastrointestinal losses. (American College of Endocrinology & AACE) 1
  • In patients with mild‑to‑moderate asthma or COPD, esmolol’s β1‑selectivity makes it preferable to non‑selective agents such as propranolol, though bronchospasm remains a risk. (Praxis Medical Insights, 2026) – expert consensus. 3
  • Active bronchospastic asthma is a relative contraindication; esmolol should be used only when benefits outweigh risks and no alternative exists. (Praxis Medical Insights, 2026) – expert consensus. 3
  • Initiate therapy in reactive airway disease at a lower infusion rate (≈ 25 µg/kg/min) with slow titration and continuous pulmonary monitoring. (Praxis Medical Insights, 2026) – expert consensus. 3

REFERENCES

1

hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the american thyroid association and american association of clinical endocrinologists. [LINK]

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2011

2

Metoprolol Dose Escalation for Rate Control in Thyrotoxicosis [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

3

Beta‑Blocker Therapy in Hyperthyroidism: Indications, Agent Selection, Dosing, and Monitoring [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026